Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Synta’s Melanoma Phase III Could Pack More Punch

21 Mar 2008

• By Randall Osborne

Statistical power may reach 99 percent, company says.

Related Content

Pfizer Hits Acquisition Trifecta: Snaps Up Serenex Hsp90 Candidate, Compound Library And Discovery Platform

03 Mar 2008

AstraZeneca/Array’s AZD6244 Fails Phase II For Melanoma

20 Dec 2007

GlaxoSmithKline Finds ‘Synta’ergy With $1 Billion Deal For Oncology Candidate

10 Oct 2007

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.